Why GLP-1 success in the real world looks different than in trials In the evolving landscape of GLP-1 trends, Ozempic (semaglutide) has garnered attention for its weight loss effects
This effect appears, however, to be limited by concomitant reductions in the inherent efficacy of ligand-bound receptors such that the peak efficacy does not continue to increase throughout the full range of internalization
Disclosures: Joseph Ahn: Nothing to Disclose, Nothing to Disclose, Hyunseok Kim: Nothing to Disclose, Michael Luu: Nothing to Disclose, Alexander Kuo: Nothing to Disclose, Walid Ayoub: Intercept: Speaking and Teaching, Mirum: Grant/Research Support, GSK: Consultant, GSK: Grant/Research Support, Madrigal: Grant/Research Support, Cymabay: Consultant, Ipsen: Grant/Research Support, Zydus: Grant/Research Support, Hirsh Trivedi: Nothing to Disclose, Yun Wang: Nothing to Disclose, Aarshi Vipani: Nothing to Disclose, Tsuyoshi Todo: Nothing to Disclose, Steven Wisel: Nothing to Disclose, Todd Brennan: Nothing to Disclose, Justin Steggerda: Nothing to Disclose, Joe Schwab: Nothing to Disclose, Irene Kim: Nothing to Disclose, Kambiz Kosari: Nothing to Disclose, Neehar Parikh: Genentech: Grant/Research Support, Exelixis: Grant/Research Support, Exelixis: Consultant, AstraZeneca: Consultant, Exact Sciences: Grant/Research Support, Exact Sciences: Consultant, Fujifilm Medical: Advisor, Amit Singal: Genentech: Consultant, AstraZeneca: Consultant, Bayer: Consultant, Eisai: Consultant, Exelixis: Consultant, Merck: Consultant, Elevar: Consultant, FujiFilm Medical Sciences: Consultant, Exact Sciences: Consultant, Glycotest: Consultant, Boston Scientific: Consultant, Sirtex: Consultant, HistoSonics: Consultant, Ju Dong Yang: Nothing to Disclose 1819 LIVER TRANSPLANTATION IS THE MAJOR DETERMINANT IN ACHIEVING OVER 10-YEAR SURVIVAL FOR PATIENTS WITH EARLY-STAGE HEPATOCELLULAR CARCINOMA Joseph Ahn 1 Hyunseok Kim 2 Michael Luu 2 Alexander Kuo 2 Walid Ayoub 2 Hirsh Trivedi 2 Yun Wang 2 Aarshi Vipani 2 Tsuyoshi Todo 2 Steven Wisel 2 Todd Brennan 2 Justin Steggerda 2 Joe Schwab 2 Irene Kim 2 Kambiz Kosari 2 Neehar Parikh 3 Amit Singal 4 Ju Dong Yang 2 , 1 Mayo Clinic, 2 Cedars-Sinai Medical Center, 3 University of Michigan Medical Center, 4 UT Southwestern Medical Center Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with prognosis heavily dependent on the stage at diagnosis and treatment modalities
NADPH oxidase-mediated induction of reactive oxygen species and extracellular matrix deposition by insulin-like growth factor binding protein-5
